D. Petrylak

Quality of life impact of three different doses of suramin in patients with metastatic hormone‐refractory prostate carcinoma

J. Holland, M. Ratain, David Palchak, 2004, Cancer.

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma

M. Galsky, D. Bajorin, J. Rosenberg, 2021, Clinical genitourinary cancer.

Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer

A. Yagoda, Alan Yagoda, Daniel Petrylak, 1993, Cancer.

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.

A. Armstrong, E. Small, C. Sternberg, 2013, Journal of the National Cancer Institute.

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

G. Rosner, M. Ratain, David Palchak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

H. Scher, D. Dershaw, A. Seidman, 1992, The Journal of urology.

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.

C. Cordon-Cardo, V. Reuter, W. Fair, 1992, Journal of the National Cancer Institute.

Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.

C. Cordon-Cardo, V. Reuter, H. Scher, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.